Literature DB >> 26490984

Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer.

Jin Hong1, Yan Mao2, Xiaosong Chen1, Li Zhu1, Jianrong He1, Weiguo Chen1, Yafen Li1, Lin Lin3, Xiaochun Fei4, Kunwei Shen5.   

Abstract

Inflammation and tumor immune microenviroment are critical factors for prognosis in numerous cancers. The aim of this study was to determine the prognostic value of preoperative neutrophil-to-lymphocyte ratio (NLR) in breast cancer. We performed a retrospective analysis of 487 patients diagnosed with primary breast cancer at Shanghai Ruijin hospital from January 2009 to December 2010. Hematological parameters before surgery, clinicopathological data, and survival status were obtained. Survival analysis was used to evaluate the prognostic value of NLR. The optimal cutoff value was determined as 1.93 for NLR and the median follow-up time was 55.0 months. On univariate analysis, patients with high NLR (>1.93) had worse 5-year disease-free survival (DFS) compared to those with low NLR (77.9 vs 88.0 %, p = 0.002). Regarding overall survival, there was no significant difference between patients with high NLR and low NLR, with 5-year overall survival of 90.8 and 91.7 % (p = 0.707). In triple-negative breast cancer, patients with high NLR was associated with worse 5-year DFS compared with patients with low NLR (63.4 vs 84.9 %, p = 0.040). Mutivariate analysis revealed that NLR was an independent prognostic factor for DFS in breast cancer (HR = 1.867, 95 % confidence interval; (95%CI) = 1.155-3.017, p = 0.011). Preoperative NLR is an independent predictor of DFS in breast cancer patients, especially in triple-negative subtype. Further studies are required to validate the prognostic value of NLR before clinical application.

Entities:  

Keywords:  Breast cancer; Disease-free survival; Molecular subtype; Neutrophil-to-lymphocyte ratio

Mesh:

Year:  2015        PMID: 26490984     DOI: 10.1007/s13277-015-4233-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  42 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression.

Authors:  Marisa M Queen; Randall E Ryan; Ryan G Holzer; Cynthia R Keller-Peck; Cheryl L Jorcyk
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

3.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

4.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

Authors:  Sahar M A Mahmoud; Emma Claire Paish; Desmond G Powe; R Douglas Macmillan; Matthew J Grainge; Andrew H S Lee; Ian O Ellis; Andrew R Green
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

5.  Cyclin E and survival in patients with breast cancer.

Authors:  Khandan Keyomarsi; Susan L Tucker; Thomas A Buchholz; Matthew Callister; Ye Ding; Gabriel N Hortobagyi; Isabelle Bedrosian; Christopher Knickerbocker; Wendy Toyofuku; Michael Lowe; Thaddeus W Herliczek; Sarah S Bacus
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

Review 6.  Gene expression profiling in breast cancer: classification, prognostication, and prediction.

Authors:  Jorge S Reis-Filho; Lajos Pusztai
Journal:  Lancet       Date:  2011-11-19       Impact factor: 79.321

Review 7.  Breast cancer in China.

Authors:  Lei Fan; Kathrin Strasser-Weippl; Jun-Jie Li; Jessica St Louis; Dianne M Finkelstein; Ke-Da Yu; Wan-Qing Chen; Zhi-Ming Shao; Paul E Goss
Journal:  Lancet Oncol       Date:  2014-06       Impact factor: 41.316

8.  Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model.

Authors:  H Schmidt; L Bastholt; P Geertsen; I J Christensen; S Larsen; J Gehl; H von der Maase
Journal:  Br J Cancer       Date:  2005-08-08       Impact factor: 7.640

9.  Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.

Authors:  Lawrence Fong; Peter Carroll; Vivian Weinberg; Stephen Chan; Jera Lewis; John Corman; Christopher L Amling; Robert A Stephenson; Jeffrey Simko; Nadeem A Sheikh; Robert B Sims; Mark W Frohlich; Eric J Small
Journal:  J Natl Cancer Inst       Date:  2014-09-24       Impact factor: 13.506

10.  Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients.

Authors:  Hany Noh; Minseob Eomm; Airi Han
Journal:  J Breast Cancer       Date:  2013-03-31       Impact factor: 3.588

View more
  14 in total

1.  Blood cadmium levels associated with short distant metastasis-free survival time in invasive breast cancer.

Authors:  Yuanfang He; Lin Peng; Yanhong Huang; Caixia Liu; Shukai Zheng; Kusheng Wu
Journal:  Environ Sci Pollut Res Int       Date:  2017-10-09       Impact factor: 4.223

2.  Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.

Authors:  S Chae; K M Kang; H J Kim; E Kang; S Y Park; J H Kim; S H Kim; S W Kim; E K Kim
Journal:  Curr Oncol       Date:  2018-04-30       Impact factor: 3.677

3.  Metastatic axillary node ratio predicts recurrence and poor long-term prognosis in patients with advanced stage IIIC (pN3) breast cancer.

Authors:  Min Hee Hur; SeungSang Ko
Journal:  Ann Surg Treat Res       Date:  2017-04-27       Impact factor: 1.859

Review 4.  Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis.

Authors:  Josee-Lyne Ethier; Danielle Desautels; Arnoud Templeton; Prakesh S Shah; Eitan Amir
Journal:  Breast Cancer Res       Date:  2017-01-05       Impact factor: 6.466

5.  Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis.

Authors:  Xu Liu; Jing-Kun Qu; Jia Zhang; Yan Yan; Xi-Xi Zhao; Ji-Zhao Wang; Hang-Ying Qu; Lin Liu; Jian-Sheng Wang; Xiao-Yi Duan
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

6.  The Pretreatment Neutrophil/Lymphocyte Ratio Is Associated with All-Cause Mortality in Black and White Patients with Non-metastatic Breast Cancer.

Authors:  Joseph Rimando; Jeff Campbell; Jae Hee Kim; Shou-Ching Tang; Sangmi Kim
Journal:  Front Oncol       Date:  2016-03-31       Impact factor: 6.244

7.  Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

Authors:  Yun Yeong Kim; Heung Kyu Park; Kyung Hee Lee; Kwan Il Kim; Yong Soon Chun
Journal:  J Breast Cancer       Date:  2016-06-24       Impact factor: 3.588

Review 8.  The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis.

Authors:  Bajin Wei; Minya Yao; Chunyang Xing; Wei Wang; Jia Yao; Yun Hong; Yu Liu; Peifen Fu
Journal:  Onco Targets Ther       Date:  2016-09-08       Impact factor: 4.147

Review 9.  Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review.

Authors:  Iléana Corbeau; William Jacot; Séverine Guiu
Journal:  Cancers (Basel)       Date:  2020-04-13       Impact factor: 6.639

10.  Neutrophil-to-lymphocyte ratio, obesity, and breast cancer risk in Chinese population.

Authors:  Qiong Fang; Yi-Wei Tong; Gen Wang; Nan Zhang; Wei-Guo Chen; Ya-Fen Li; Kun-Wei Shen; Bei-Wen Wu; Xiao-Song Chen
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.